MarketPulse

Ozempic

4 articles
BenzingaBenzinga··Vandana Singh

India's Generic Semaglutide Flood Slashes Ozempic Costs by 70%, Reshaping Global Obesity Market

Over 40 Indian pharma companies launched generic semaglutide after patent expiration, pricing treatments 70% below Novo Nordisk's originals. Market expansion planned globally.
NVOHIMSRDYweight loss drugsobesity market
The Motley FoolThe Motley Fool··Geoffrey Seiler

Hims & Hers Surges 40% on Novo Nordisk Deal, But Valuation Concerns Linger

Hims & Hers surges 40% after Novo Nordisk partnership resolves litigation, enabling authorized distribution of Wegovy and Ozempic. Stock trades under 20x forward P/E.
NVOHIMSGLP-1 drugstelemedicine
BenzingaBenzinga··Vandana Singh

Novo Nordisk Cuts GLP-1 Drug Prices 50% Amid Clinical Setbacks

Novo Nordisk cuts GLP-1 drug prices 50% to $675/month starting 2027 amid clinical setbacks and competitive pressure from rivals like Eli Lilly.
LLYNVOclinical trialprice reduction
The Motley FoolThe Motley Fool··Rich Smith

Novo Nordisk Stock Pullback Creates Entry Point for Long-Term GLP-1 Investors

Novo Nordisk stock down 67% offers entry point for long-term investors. Strong GLP-1 market position, attractive valuation metrics, and growth potential despite upcoming competition.
LLYNVOstock valuationdividend stocks